Evidence map›Paper›PMID 41073682›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2025

Risk of liver dysfunction with ACE inhibitors based on real-world data from the MID-NET

Yuki Kinoshita, Takashi Ando, Kazuhiro Kajiyama, Hotaka Maruyama, Mei Kohama, Ayumi Tanaka, Yusuke Matsunaga, Chieko Ishiguro, Takahiro Nonaka, Naoya Horiuchi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuki Kinoshita *Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Takashi Ando *Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Kazuhiro KajiyamaOffice of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Hotaka MaruyamaOffice of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Mei KohamaOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Ayumi TanakaOffice of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Yusuke MatsunagaOffice of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Chieko IshiguroOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Takahiro NonakaOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Naoya HoriuchiOffice of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Taihei TanakaOffice of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Yoshiaki UyamaOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. uyama-yoshiaki@pmda.go.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Warnings about liver dysfunction in Japanese package inserts vary among angiotensin-converting enzyme (ACE) inhibitors, and risk assessment of liver dysfunction with ACE inhibitors has been limited. To evaluate the risk of liver dysfunction among patients prescribed ACE inhibitors available in Japan, we conducted this study based on the real-world data from MID-NET

Indexed as

Angiotensin-Converting Enzyme InhibitorsChemical and Drug Induced Liver InjuryAgedFemaleHumansJapanMaleMiddle AgedAngiotensin-Converting Enzyme InhibitorsAngiotensin-converting enzyme inhibitorsHypertensionLiver dysfunctionPharmacoepidemiologySafety measure

Identifiers

PMID41073682
PMCPMC12678171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.